Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Global Microfluidics Market Assessment 2026: Set to Expand Through 2033 as Point-of-Care Diagnostics, Drug Discovery and Lab-on-a-Chip Innovation Drive New Growth OpportunitiesDemand for rapid diagnostics, personalized medicine and drug screening is driving microfluidics, creating opportunities in lab-on-chip, wearables, AI automation and emerging markets
- Global Wearable Biosensors Market Trends, Strategies and Forecast to 2036 Featuring Abbott Labs, Dexcom, Medtronic, Roche, Apple, Samsung Electronics Co., Garmin and Other Key PlayersCompanies: DexcomGarmin Ltd.Medtronic plcRoche HoldingSamsung Electronics"Wearable Biosensors Market - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering. According to the research report, the global wearable biosensors market is projected to reach USD 105.5 billion by 2036 from USD 35.5 billion in 2026, growing at a CAGR of 12.5% during the forecast period (2026-2036). The growth of this market is primarily driven by the escalating demand for continuous health monitoring, the rising prevalence of chronic diseases such as diabetes and cardiovascular conditions, and the increasing adoption of personalized healthcare solutions. Wearable biosensors are sophisticated devices that enable real-time tracking of physiological parameters, providing critical data for early disease detection and remote patient management. The global wearable biosensors market is undergoing a profound structural transformation as the healthcare industry shifts from episodic, clinic-based care toward continuous, proactive health management. This evolution is being catalyzed by the rapid miniaturization of sensing technologies and the integration of advanced data analytics and artificial intelligence into consumer wearables. The industry is witnessing a significant transition from simple activity trackers toward medical-grade diagnostic devices that can monitor complex biomarkers like glucose, blood pressure, and cardiac rhythms with high precision. Furthermore, the integration of wearable biosensors with digital health and telemedicine platforms is creating a seamless ecosystem for remote patient monitoring and virtual care delivery. This dynamic shift ensures sustained demand for non-invasive, user-friendly sensing solutions that empower individuals and healthcare providers with actionable health insights, ultimately improving clinical outcomes and reducing healthcare costs. Market Segmentation The global wearable biosensors market is segmented by biomarker type (glucose monitoring, heart rate and cardiac biomarkers, blood oxygen [SpO2] monitoring, blood pressure monitoring, lactate and performance biomarkers, and other biomarkers), product type/form factor (smartwatches, fitness bands, continuous glucose monitoring devices, wearable ECG monitors, smart patches, smart rings, and smart clothing), application (clinical and medical, fitness and wellness, and sports and performance monitoring), end-user (hospitals and clinics, home care settings, fitness and sports organizations, individual consumers, and research institutions), and geography. The study evaluation includes industry competitors and analyzes the market at the country level. Based on Biomarker Type By biomarker type, the glucose monitoring segment is expected to hold the largest share of the global wearable biosensors market in 2026. This dominance is attributed to the high and rising prevalence of diabetes globally and the widespread adoption of continuous glucose monitoring (CGM) systems that eliminate the need for frequent finger-prick testing. Conversely, the heart rate and cardiac biomarkers segment is projected to register significant growth, driven by the increasing integration of ECG and heart rate variability (HRV) sensing into consumer smartwatches, enabling early detection of arrhythmias and other cardiovascular conditions. Furthermore, the lactate and multi-analyte biosensors segments are projected to register the highest CAGR during the forecast period, fueled by the growing demand for performance optimization in sports and the development of non-invasive sensors for comprehensive metabolic health tracking. Based on Product Type / Form Factor By product type/form factor, the smartwatches with integrated biosensors segment is expected to hold the largest share of the global wearable biosensors market in 2026. Smartwatches have become the primary platform for health monitoring due to their high consumer acceptance, multi-functionality, and the continuous addition of medical-grade sensors by leading tech companies. Meanwhile, the continuous glucose monitoring devices segment is projected to register the highest CAGR during the forecast period. This rapid growth is driven by the shift toward proactive diabetes management and the expansion of CGM use among non-insulin-dependent patients and health-conscious individuals. Additionally, smart patches and smart rings are emerging as high-growth segments, offering discrete and specialized monitoring for clinical and wellness applications. Based on Application By application, the clinical and medical segment is expected to hold the largest share in 2026. The increasing use of wearable biosensors for chronic disease management, post-operative monitoring, and clinical trials drives this segment's leadership. Within this segment, remote patient monitoring (RPM) is a major growth catalyst. Conversely, the fitness and wellness segment is projected to register a steady growth rate, driven by the increasing consumer focus on preventive health and the popularity of activity and sleep tracking. The sports and performance monitoring segment is also witnessing rapid expansion as professional athletes and fitness enthusiasts adopt biosensors to optimize training and recovery through data-driven insights. Based on End-User By end-user, the hospitals and clinics segment is expected to hold the largest share in 2026, reflecting the primary role of healthcare providers in prescribing and managing medical-grade wearable sensors for patient care. Conversely, the home care settings segment is projected to register the highest CAGR during the forecast period. This rapid growth is driven by the global trend toward decentralized healthcare and the increasing preference for monitoring patients in their home environments to improve comfort and reduce hospital readmissions. The individual consumers segment also remains significant, as more people purchase wearables for personal health and fitness tracking. Geographic Analysis In 2026, North America is expected to account for the largest share of the global wearable biosensors market. The region's leadership is underpinned by a highly advanced healthcare infrastructure, high levels of digital health literacy, and the presence of industry leaders such as Abbott, Dexcom, Apple, and Medtronic in the United States. Furthermore, the early adoption of remote patient monitoring and a favorable reimbursement landscape for digital health technologies contribute to the market's dominance. Key companies in the North America market include Abbott Laboratories (U.S.), Dexcom, Inc. (U.S.), Apple Inc. (U.S.), Medtronic plc (Ireland), Garmin Ltd. (U.S.), Google LLC (Fitbit - U.S.), Masimo Corporation (U.S.), VitalConnect, Inc. (U.S.), and Biolinq Inc. (U.S.). Asia-Pacific is projected to witness the fastest growth during the forecast period. This expansion is primarily driven by increasing healthcare expenditure, the rapid expansion of the middle-class population, and the high penetration of smartphones and wearable devices in China, India, and Japan. Furthermore, the rising burden of chronic diseases in the region and government initiatives to promote digital health are significant catalysts. Key companies in the Asia-Pacific market include Samsung Electronics Co., Ltd. (South Korea) and various emerging local MedTech startups. Europe remains a critical market for wearable biosensors, characterized by a strong focus on preventive healthcare and the implementation of robust medical device regulations. European countries are increasingly adopting wearable sensors to address the healthcare needs of an aging population and to improve the efficiency of public health systems. The region's focus on data privacy and security is driving the demand for sensors that comply with strict GDPR and MDR standards. Key companies in the Europe market include F. Hoffmann-La Roche Ltd. (Switzerland), Oura Health Ltd. (Finland), and Empatica Inc. (U.S./Italy). Latin America is an emerging market for wearable biosensors, driven by the modernization of healthcare facilities and the increasing adoption of consumer health technologies in Brazil and Mexico. The region is seeing a shift toward more accessible health monitoring solutions as enterprises and individuals seek to manage chronic conditions more effectively. The Middle East & Africa region is experiencing growing interest in wearable biosensors as part of national digital health transformation strategies, particularly in the UAE and Saudi Arabia. Investments in high-tech healthcare infrastructure and the adoption of AI-driven health solutions are expected to be major drivers of market growth in the region. Key Players The key players operating in the global wearable biosensors market include:
- Analysis of Mexico's ICT Market 2026-2034 | Set to Reach USD 158.9 Billion by 2034, Driven by Cloud Adoption and Digital TransformationCloud adoption, digital transformation, remote work, AI, IoT, 5G and cybersecurity demand are creating opportunities across Mexico’s software, IT services and telecom sectors
- Walrus Pump Enters the AI Data Center Cooling MarketFrom Pumps to Liquid Cooling System Integration
- Customer-Centric "Huawei + Partners" Collaboration System Launched to Scale AI Across IndustriesCompanies: HuaweiAt HUAWEI CONNECT 2026, Leo Chen, Huawei's Senior Vice President and President of Enterprise Sales, announced the new SCALE partner support system during his "Scaling All Intelligence for Industry Success" keynote address. Huawei intends to use...
- Huawei Releases Intelligent WAN Target Architecture for ISPsCompanies: Huawei—Fortifying the Connectivity Foundation for ISP AI Services — On September 17, during HUAWEI CONNECT 2026, the roundtable themed "Intelligent WAN, Fortifying the AI Services Connectivity Foundation for ISPs" concluded in Shanghai. The event brought...
- ABB’s new direct current portfolio aims to rewire AI data center energy infrastructureCompanies: ABB GroupABB today announced the launch of Infinitus, a portfolio of direct current (DC) solutions designed to manage the increasing power demands of AI data centers. The portfolio will accelerate the adoption of DC architectures in data centers, improving energy efficiency and reducing power infrastructure footprint, while increasing available computing capacity. ABB expects other energy-intensive industries to make the same transition.
- OpenAIExpanding OpenAI Academy with new learning pathsCompanies: OpenAIExplore new OpenAI Academy learning paths for employees, developers, leaders, educators, and students to build and demonstrate practical AI skills.
- Banking Fraud to Reach 2.2 billion Transactions by 2031, Fuelled by Growing AI-enabled AttacksJuniper Research revealed fraudulent transactions in digital banking and money transfer will surpass 2.2 billion globally by 2031.
- Duiba Group Founder Gifts 11.21% Stake to Employee Incentive Platform in Record-High Founders-to-ESOP Transfer by Share of Capital in Hong Kong Market HistoryHONG KONG, Sept 21, 2026 - Duiba Group Limited (Stock Code: 01753.HK), the Hong Kong-listed operator that has become one of China's fastest-scaling AI short-drama platforms, announced that its controlling shareholder, Xiaoliang Holding Limited, has agreed to transfer 120,682,000 ordinary shares — approximately 11.21% of issued share capital — for nil consideration to Kewei Holding Limited, the Company's employee share award platform. The transfer, executed on 20 September 2026, is understood to be the largest founder-to-ESOP donation by percentage of share capital in the history of the Hong Kong stock market. It is not a disposal for cash. No shares are being sold into the market; all of them are being placed into a vehicle whose sole economic purpose is to reward and retain employees. Crucially, the arrangement is being funded entirely from the founder's personal shareholding. It involves no issuance of new shares and therefore no dilution to existing shareholders, and it consumes no company capital — no cash, no treasury reserves, no debt. The 120,682,000 shares are being transferred at nil consideration from the founder's own account to the employee incentive platform, meaning the cost of motivating and retaining the core team is borne by the founder, not by public investors or the Company's balance sheet. Six months of exponential growth The transfer comes as Duiba's AI short-drama business enters a phase of compounding growth. On Douyin's native end, cumulative playback from June to August rose 178%. In July and August, Duiba ranked top three across the entire industry for two consecutive months, and was the only leading player to sustain month-on-month growth above 50% in both months. Seven years, zero founder selling Duiba listed on the Main Board of The Stock Exchange of Hong Kong on 7 May 2019. According to HKEX disclosure records, Mr. Chen Xiaoliang, the founder and controlling shareholder, voluntarily extended the post-IPO lock-up to three years at the time of listing and, from the IPO through the date of the transfer, has never reduced his personal beneficial shareholding. The 20 September arrangement is therefore the first change in the founder's ownership structure in the seven years since listing — and its direction is unambiguously inward. "This is the clearest possible signal that the controlling shareholder is backing the next chapter of the business rather than exiting it," a Company spokesperson said. "The shares go to an ESOP vehicle, not to the market." After completion, Xiaoliang Holding will remain the controlling shareholder with approximately 31.01%, down from 42.21%. Kewei Holding, which currently holds only 0.17%, will hold approximately 11.38%. A war chest for AI talent Kewei Holding has undertaken to introduce new incentive schemes with vesting and lock-up arrangements under the Company's equity incentive management measures. The stated focus is AI businesses, with AI short drama at the centre. Existing and future awards will be subject to service and performance conditions, aligning key employees with long-term shareholder value. The timing is deliberate. The AI short-drama sector is expanding rapidly, but hits remain scarce: fewer than 0.5% of new AI short dramas on Douyin surpass 100 million views. In that environment, the constraint on growth is not capital — it is the ability to retain writers, algorithm engineers, producers and commercialisation talent capable of turning AI tooling into repeatable hits. By moving roughly 11% of the Company into a locked-up, performance-vested incentive pool, Duiba is, in effect, converting founder ownership into collective engineering and creative capacity. The AI bet is already compounding Duiba was founded in 2014, is headquartered in Hangzhou and listed on HKEX in May 2019. It built its early business on points-and-benefits SaaS and internet advertising, serving more than 16,000 enterprise clients. In late 2025 it moved strategically into AI short drama, building a full-stack pipeline spanning AI scriptwriting, AI production and AI distribution — what the Company describes as the industrialised, scaled monetisation of AI-generated content. Financials: revenue and gross profit rising in tandem The Company's 2026 interim results show that the growth is reaching the income statement, not merely the traffic ledger. For the six months ended 30 June 2026: Metric 1H2026 Change Total revenue RMB 434.7 million +24.3% YoY Gross profit RMB 74.5 million +30.0% YoY Gross margin 17.1% 16.4% (1H2025) Loss attributable to owners RMB 25.3 million narrowed AI short-drama revenue RMB 222.6 million 51.2% of group revenue The Group's traditional SaaS and advertising operations contributed nearly RMB 70 million of gross profit in the first half and are expected to continue providing earnings support, while AI short drama has become the dominant revenue driver. Asset quality also appears intact. The Company reported net assets of RMB 1.175 billion, cash and short-term wealth management products of approximately RMB 400 million, and prepayments of RMB 345 million, largely related to the bank instant-discount business and recyclable into working capital. Why the transfer matters now Three things make the move more than a symbolic gesture. First, it is structurally a gift, not a sale. The nil-consideration transfer means the founder receives no cash. For a controlling shareholder who has not sold a single share in seven years, the decision moves equity from a personal account to a collective one. Second, it arrives at a moment of operational inflection. Douyin rankings, view-count trajectories and the first-half revenue split all point in the same direction: AI short drama has become the core business, and locking talent into it via vesting and lock-ups addresses the binding constraint on its next phase. Third, it creates a credible incentive currency. An ESOP pool of roughly 11.38% is large enough to be material for hires and retention, yet structured with vesting and lock-ups that prevent it from becoming a short-term payout. The road ahead: overseas expansion and the short drama alliance business Duiba's second-half outlook rests on two tracks: AI short-drama expansion and a stable SaaS and advertising base. On the global front, the Company is accelerating its overseas push into a market it estimates at US$4 billion in 2026, up 390% year on year, with management expecting overseas operations to begin contributing revenue in the fourth quarter. Domestically, it is pursuing a strategy of the short drama alliance business,expanding to tens of thousands of app media clients via SDK access. Its distribution footprint extends beyond Toutiao and Hongguo to Tencent, Kuaishou, Baidu and more than 20 mid-tier platforms. This is not a founder exit. It is a founder-to-employee capital allocation: a seven-year holder converting personal ownership into collective incentive capacity at precisely the moment Duiba's AI short-drama business is compounding on both the view-count and income-statement lines.
- IBMNew IBM CHRO Study: AI Puts Critical Thinking at the Center of Workforce PrioritiesCompanies: IBM• 60% of employees worry AI is eroding their skills, with critical thinking cited most often as declining
- ConveraConvera and JustLogin Partner to Enable Cross-Border Payroll and Payments Across Singapore and Southeast AsiaPartnership brings regulated, multi-currency payments into everyday HR workflows, supporting companies as they scale teams, payroll and operations — Convera, a global leader in commercial payments, and JustLogin, an AI-Powered...